Is there any role for radium-223 early in the course of castration-resistant prostate cancer with bone metastases?
Typically radium-223 is reserved for men with symptomatic bone disease after failure of multiple other therapies. Is there a population of men who may be better served by introducing radium-223 earlier in the treatment course?
Answer from: Medical Oncologist at Academic Institution
In the ALSYMPCA trial, there was a demonstrated benefit of radium-223 on survival and skeletal event delay, regardless of prior docetaxel (Hoskin et al Lancet Oncol 2014), indicating that it is not necessary to give docetaxel first before radium and that radium has clear activity in earlier mCRPC (s...
Sign in or Register to read more